Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Amneal Pharmaceuticals Inc (NASDAQ: AMRX) closed at $12.87 up 0.23% from its previous closing price of $12.84. In other words, the price has increased by $0.23 from its previous closing price. On the day, 0.81 million shares were traded. AMRX stock price reached its highest trading level at $12.97 during the session, while it also had its lowest trading level at $12.75.
Ratios:
For a deeper understanding of Amneal Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.14 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.21. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 2.13.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $15.
On June 06, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $12.
JP Morgan Upgraded its Neutral to Overweight on February 24, 2025, whereas the target price for the stock was revised from $9 to $12.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 17 ’25 when Nark Ted C sold 50,000 shares for $11.72 per share. The transaction valued at 586,000 led to the insider holds 291,029 shares of the business.
Nark Ted C bought 50,000 shares of AMRX for $591,250 on Nov 17 ’25. On Nov 12 ’25, another insider, Shah Nikita, who serves as the Executive Vice President of the company, sold 131,856 shares for $11.92 each. As a result, the insider received 1,571,724 and left with 146,403 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMRX now has a Market Capitalization of 4045850624 and an Enterprise Value of 6595382784. As of this moment, Amneal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 906.34, and their Forward P/E ratio for the next fiscal year is 13.89. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.56. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.38. Its current Enterprise Value per Revenue stands at 2.247 whereas that against EBITDA is 10.573.
Stock Price History:
The Beta on a monthly basis for AMRX is 1.35, which has changed by 0.6457801 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, AMRX has reached a high of $12.97, while it has fallen to a 52-week low of $6.68. The 50-Day Moving Average of the stock is 11.21%, while the 200-Day Moving Average is calculated to be 39.62%.
Shares Statistics:
For the past three months, AMRX has traded an average of 1.80M shares per day and 2103360 over the past ten days. A total of 314.31M shares are outstanding, with a floating share count of 156.78M. Insiders hold about 50.13% of the company’s shares, while institutions hold 44.16% stake in the company. Shares short for AMRX as of 1765756800 were 5336430 with a Short Ratio of 2.97, compared to 1763078400 on 6575260. Therefore, it implies a Short% of Shares Outstanding of 5336430 and a Short% of Float of 2.6400002.
Earnings Estimates
Investors are keenly observing as 5.0 analysts analyze and rate. The current performance of Amneal Pharmaceuticals Inc (AMRX) in the stock market.The consensus estimate for the next quarter is $0.19, with high estimates of $0.21 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.82 and $0.78 for the fiscal current year, implying an average EPS of $0.8. EPS for the following year is $0.93, with 5.0 analysts recommending between $1.03 and $0.86.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $808.14M this quarter.It ranges from a high estimate of $822.7M to a low estimate of $790.11M. As of. The current estimate, Amneal Pharmaceuticals Inc’s year-ago sales were $730.52MFor the next quarter, 4 analysts are estimating revenue of $741.79M. There is a high estimate of $748.71M for the next quarter, whereas the lowest estimate is $728.7M.
A total of 4 analysts have provided revenue estimates for AMRX’s current fiscal year. The highest revenue estimate was $3.03B, while the lowest revenue estimate was $2.99B, resulting in an average revenue estimate of $3.01B. In the same quarter a year ago, actual revenue was $2.79BBased on 4 analysts’ estimates, the company’s revenue will be $3.21B in the next fiscal year. The high estimate is $3.23B and the low estimate is $3.18B.
